The Global Health Body Sounds Warning Over Severe Shortage of Obesity Jabs
Under a tenth of people who could benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it releases its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a lifelong illness that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are significant hurdles to universal access to the injections that can aid individuals in losing significant body mass, says the organization.
GLP-1 Therapy Scarcity
Even in the present best projected case, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, per the WHO.
The guideline urges governments and firms to increase access, by strategies including patent sharing.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Operate
The injections replicate a natural hormone to slow digestion, reduce hunger and enhance satiety so individuals eat less.
Patients typically see weight reduction after several weeks of commencing the regular doses.
Research suggests users may see weight return after a year of halting the medication, as their typical appetite return.
To be above a healthy weight raises your chance for experiencing diseases, including type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
